ID   CARD9_RAT               Reviewed;         536 AA.
AC   Q9EPY0; F1LQK8;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   02-OCT-2024, entry version 136.
DE   RecName: Full=Caspase recruitment domain-containing protein 9 {ECO:0000303|PubMed:11053425};
DE            Short=rCARD9 {ECO:0000303|PubMed:11053425};
GN   Name=Card9 {ECO:0000303|PubMed:11053425, ECO:0000312|RGD:708370};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RX   PubMed=11053425; DOI=10.1074/jbc.c000726200;
RA   Bertin J., Guo Y., Wang L., Srinivasula S.M., Jacobson M.D., Poyet J.-L.,
RA   Merriam S., Du M.-Q., Dyer M.J.S., Robison K.E., DiStefano P.S.,
RA   Alnemri E.S.;
RT   "CARD9 is a novel caspase recruitment domain-containing protein that
RT   interacts with Bcl10/CLAP and activates NF-kappa B.";
RL   J. Biol. Chem. 275:41082-41086(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3]
RP   PHOSPHORYLATION AT THR-531 AND THR-533, MUTAGENESIS OF THR-526; SER-528;
RP   THR-531 AND THR-533, FUNCTION, AND INTERACTION WITH VHL.
RX   PubMed=17936701; DOI=10.1016/j.molcel.2007.09.010;
RA   Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X.,
RA   Zhang L., Kim W.Y., Olumi A.F., Kaelin W.G. Jr.;
RT   "pVHL acts as an adaptor to promote the inhibitory phosphorylation of the
RT   NF-kappaB agonist Card9 by CK2.";
RL   Mol. Cell 28:15-27(2007).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-424; SER-425; SER-451
RP   AND SER-461, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Adapter protein that plays a key role in innate immune
CC       response against fungi by forming signaling complexes downstream of C-
CC       type lectin receptors (By similarity). CARD9-mediated signals are
CC       essential for antifungal immunity against a subset of fungi from the
CC       phylum Ascomycota (By similarity). Transduces signals in myeloid cells
CC       downstream of C-type lectin receptors CLEC7A (dectin-1), CLEC6A
CC       (dectin-2) and CLEC4E (Mincle), which detect pathogen-associated
CC       molecular pattern metabolites (PAMPs), such as fungal carbohydrates,
CC       and trigger CARD9 activation (PubMed:17936701). Upon activation, CARD9
CC       homooligomerizes to form a nucleating helical template that recruits
CC       BCL10 via CARD-CARD interaction, thereby promoting polymerization of
CC       BCL10 and subsequent recruitment of MALT1: this leads to activation of
CC       NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14)
CC       pathways which stimulate expression of genes encoding pro-inflammatory
CC       cytokines and chemokines (PubMed:17936701). CARD9 signaling in antigen-
CC       presenting cells links innate sensing of fungi to the activation of
CC       adaptive immunity and provides a cytokine milieu that induces the
CC       development and subsequent of interleukin 17-producing T helper (Th17)
CC       cells (By similarity). Also involved in activation of myeloid cells via
CC       classical ITAM-associated receptors and TLR: required for TLR-mediated
CC       activation of MAPK, while it is not required for TLR-induced activation
CC       of NF-kappa-B (By similarity). CARD9 can also be engaged independently
CC       of BCL10: forms a complex with RASGRF1 downstream of C-type lectin
CC       receptors, which recruits and activates HRAS, leading to ERK activation
CC       and the production of cytokines (By similarity). Acts as an important
CC       regulator of the intestinal commensal fungi (mycobiota) component of
CC       the gut microbiota (By similarity). Plays an essential role in
CC       antifungal immunity against dissemination of gut fungi: acts by
CC       promoting induction of antifungal IgG antibodies response in CX3CR1(+)
CC       macrophages to confer protection against disseminated C.albicans or
CC       C.auris infection (By similarity). Also mediates immunity against other
CC       pathogens, such as certain bacteria, viruses and parasites; CARD9
CC       signaling is however redundant with other innate immune responses (By
CC       similarity). In response to L.monocytogenes infection, required for the
CC       production of inflammatory cytokines activated by intracellular
CC       peptidoglycan: acts by connecting NOD2 recognition of peptidoglycan to
CC       downstream activation of MAP kinases (MAPK) without activating NF-
CC       kappa-B (By similarity). {ECO:0000250|UniProtKB:A2AIV8,
CC       ECO:0000269|PubMed:17936701}.
CC   -!- ACTIVITY REGULATION: Maintained in an autoinhibited state via
CC       homodimerization in which the CARD domain forms an extensive
CC       interaction with the adjacent linker and coiled-coil regions (By
CC       similarity). Activation downstream of C-type lectin receptors, by
CC       phosphorylation by PRKCD and/or ubiquitination by TRIM62, triggers
CC       disruption of the CARD domain-coiled coil interface, CARD9
CC       homooligomerization and BCL10 recruitment, followed by activation of
CC       NF-kappa-B and MAP kinase p38 pathways (By similarity). Zinc-binding
CC       inhibits activation by stabilizing the CARD ground-state conformation
CC       and restricting its capacity to form BCL10-nucleating filaments (By
CC       similarity). {ECO:0000250|UniProtKB:A2AIV8,
CC       ECO:0000250|UniProtKB:Q9H257}.
CC   -!- SUBUNIT: Monomer. Homodimer; homodimerization is mediated by the CARD
CC       domain which forms an extensive interaction with the adjacent linker
CC       and coiled-coil regions; leads to an autoinhibited state. Homomultimer;
CC       polymerizes following activation, forming a nucleating helical template
CC       that seeds BCL10-filament formation via a CARD-CARD interaction (By
CC       similarity). Interacts (via CARD domain) with BCL10 (via CARD domain);
CC       interaction takes place following CARD9 activation and polymerization,
CC       leading to the formation of a filamentous CBM complex assembly.
CC       Component of a CBM complex (CARD9-BCL10, MALT1), composed of CARD9,
CC       BCL10 and MALT1. Interacts with RASGRF1. Interacts with NOD2 (via NACHT
CC       domain); interaction is direct. Interacts with RIPK2 (By similarity).
CC       Interacts with VHL; without leading to protein degradation
CC       (PubMed:17936701). {ECO:0000250|UniProtKB:A2AIV8,
CC       ECO:0000250|UniProtKB:Q9H257, ECO:0000269|PubMed:17936701}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9H257}.
CC   -!- DOMAIN: The linker region, also named autoinhibitory interface, is
CC       required to prevent constitutive activation and maintain CARD9 in an
CC       autoinhibitory state. Disruption of this region triggers polymerization
CC       and activation, leading to formation of BCL10-nucleating filaments.
CC       {ECO:0000250|UniProtKB:Q9H257}.
CC   -!- PTM: Phosphorylated at Thr-231 by PRKCD downstream of C-type lectin
CC       receptors activation: phosphorylation promotes interaction with BCL10,
CC       followed by activation of NF-kappa-B and MAP kinase p38 pathways (By
CC       similarity). Phosphorylated at Thr-531 and Thr-533 by CK2 following
CC       interaction with VHL, leading to inhibit the ability to activate NF-
CC       kappa-B (PubMed:17936701). {ECO:0000250|UniProtKB:A2AIV8,
CC       ECO:0000269|PubMed:17936701}.
CC   -!- PTM: Ubiquitinated at Lys-125 via 'Lys-27'-linked ubiquitin by TRIM62
CC       downstream of C-type lectin receptors activation; leading to CARD9
CC       activation, followed by activation of NF-kappa-B and MAP kinase p38
CC       pathways. Deubiquitinated at Lys-125 by USP15, inhibiting CARD9.
CC       {ECO:0000250|UniProtKB:Q9H257}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF311288; AAG28791.1; -; mRNA.
DR   EMBL; AABR06021907; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_071639.1; NM_022303.1.
DR   AlphaFoldDB; Q9EPY0; -.
DR   SMR; Q9EPY0; -.
DR   STRING; 10116.ENSRNOP00000074450; -.
DR   iPTMnet; Q9EPY0; -.
DR   PhosphoSitePlus; Q9EPY0; -.
DR   jPOST; Q9EPY0; -.
DR   PaxDb; 10116-ENSRNOP00000025456; -.
DR   Ensembl; ENSRNOT00000091484.2; ENSRNOP00000074450.1; ENSRNOG00000051470.2.
DR   GeneID; 64171; -.
DR   KEGG; rno:64171; -.
DR   UCSC; RGD:708370; rat.
DR   AGR; RGD:708370; -.
DR   CTD; 64170; -.
DR   RGD; 708370; Card9.
DR   eggNOG; ENOG502R00K; Eukaryota.
DR   GeneTree; ENSGT00940000160570; -.
DR   HOGENOM; CLU_038057_1_0_1; -.
DR   InParanoid; Q9EPY0; -.
DR   OrthoDB; 4213113at2759; -.
DR   Reactome; R-RNO-5607764; CLEC7A (Dectin-1) signaling.
DR   PRO; PR:Q9EPY0; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000051470; Expressed in esophagus and 19 other cell types or tissues.
DR   GO; GO:0032449; C:CBM complex; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0050700; F:CARD domain binding; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:RGD.
DR   GO; GO:0061760; P:antifungal innate immune response; ISS:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; ISO:RGD.
DR   GO; GO:0051607; P:defense response to virus; ISO:RGD.
DR   GO; GO:0048874; P:host-mediated regulation of intestinal microbiota composition; ISS:UniProtKB.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; ISS:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; ISO:RGD.
DR   GO; GO:0002446; P:neutrophil mediated immunity; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISO:RGD.
DR   GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0032725; P:positive regulation of granulocyte macrophage colony-stimulating factor production; ISS:UniProtKB.
DR   GO; GO:0045089; P:positive regulation of innate immune response; ISO:RGD.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISS:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISO:RGD.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; ISO:RGD.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0051260; P:protein homooligomerization; ISS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0032663; P:regulation of interleukin-2 production; ISO:RGD.
DR   GO; GO:0032675; P:regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0032680; P:regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:1904044; P:response to aldosterone; IEP:RGD.
DR   GO; GO:0043330; P:response to exogenous dsRNA; ISO:RGD.
DR   GO; GO:0009620; P:response to fungus; ISO:RGD.
DR   GO; GO:0032495; P:response to muramyl dipeptide; ISO:RGD.
DR   GO; GO:0032494; P:response to peptidoglycan; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; ISO:RGD.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; ISO:RGD.
DR   CDD; cd08809; CARD_CARD9; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR042142; CARD_CARD9.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   PANTHER; PTHR14559; CASPASE RECRUITMENT DOMAIN FAMILY; 1.
DR   PANTHER; PTHR14559:SF3; CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9; 1.
DR   Pfam; PF00619; CARD; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   PROSITE; PS50209; CARD; 1.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Coiled coil; Cytoplasm; Immunity; Innate immunity;
KW   Isopeptide bond; Metal-binding; Phosphoprotein; Reference proteome;
KW   Ubl conjugation; Zinc.
FT   CHAIN           1..536
FT                   /note="Caspase recruitment domain-containing protein 9"
FT                   /id="PRO_0000144083"
FT   DOMAIN          6..98
FT                   /note="CARD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00046"
FT   REGION          99..116
FT                   /note="Linker"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   REGION          425..451
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          472..536
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          117..277
FT                   /evidence="ECO:0000255"
FT   COILED          303..420
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        425..442
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        484..507
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        517..536
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         3
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   BINDING         10
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   BINDING         73
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         231
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AIV8"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         425
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         431
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AIV8"
FT   MOD_RES         451
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         483
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   MOD_RES         531
FT                   /note="Phosphothreonine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:17936701"
FT   MOD_RES         533
FT                   /note="Phosphothreonine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:17936701"
FT   CROSSLNK        125
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H257"
FT   MUTAGEN         526
FT                   /note="T->A: Abolished phosphorylation by CK2 and increased
FT                   activation of NF-kappa-B; when associated with A-528; A-531
FT                   and A-533."
FT                   /evidence="ECO:0000269|PubMed:17936701"
FT   MUTAGEN         528
FT                   /note="S->A: Abolished phosphorylation by CK2 and increased
FT                   activation of NF-kappa-B; when associated with A-526; A-531
FT                   and A-533."
FT                   /evidence="ECO:0000269|PubMed:17936701"
FT   MUTAGEN         531
FT                   /note="T->A: Abolished phosphorylation by CK2 and increased
FT                   activation of NF-kappa-B; when associated with A-526; A-528
FT                   and A-533."
FT                   /evidence="ECO:0000269|PubMed:17936701"
FT   MUTAGEN         533
FT                   /note="T->A: Abolished phosphorylation by CK2 and increased
FT                   activation of NF-kappa-B; when associated with A-526; A-528
FT                   and A-531."
FT                   /evidence="ECO:0000269|PubMed:17936701"
SQ   SEQUENCE   536 AA;  62632 MW;  6F33089CB7E6BAC9 CRC64;
     MSDYENDDEC WSALESFRVK LISVIDPSRI TPYLRQCKVL NPDDEEQVLS DPNLVIRKRK
     VGVLLDILQR TGHKGYVAFL ESLELYYPQL YRKVTGKEPA RVFSMIIDAS GESGLTQLLM
     TEVMKLQKKV QDLTALLSSK DDFIKELRVK DSLLRKHQER VQRLKEECEL SSAELKRCKD
     ENYDLAMRLA HLSEEKGAAL MRNRDLQLEV DQLRHSLMKA EDDCKVERKH TLKLRHAMEQ
     RPSQELLWDL QQERDLLQAR VQELEVSVQE GKLHRNSPYI QVLEEDWRQA LQEHQEQAST
     IFSLRKDLRQ AEALRTRCME EKEMFELQCL ALRKDAKMYK DRIEAILQQM EEVSIERDQA
     MTSREELHAQ CAQSFQDKDK LRKQVRELDE KADELQLQLF QTESRLLAAE GRLKQQQLDM
     LILSSDLEDS SPRNSQELSL PQDLEEDAQL SDKGVLADRE SPEQPFVVLN KKHLSQTHDT
     VPSSSEPPEK ERRRLKESFE NYRRKRALRK MQNSWRQGEG DHGNTTGSDN TDTEGS
//
